Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0584
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial ; day:27 ; month:5 ; year:2018 ; pages:1-10
Annals of hematology ; (27.5.2018), 1-10

Urheber
Beteiligte Personen und Organisationen
Saydam, Guray
Palandri, Francesca
Benevolo, Giulia
Egyed, Miklos
Callum, Jeannie
Devos, Timothy
Sivgin, Serdar
Guglielmelli, Paola
Bensasson, Caroline
Khan, Mahmudul
Ronco, Julian Perez
Passamonti, Francesco
SpringerLink (Online service)

DOI
10.1007/s00277-018-3365-y
URN
urn:nbn:de:101:1-2018080309152093079831
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:28 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Griesshammer, Martin
  • Saydam, Guray
  • Palandri, Francesca
  • Benevolo, Giulia
  • Egyed, Miklos
  • Callum, Jeannie
  • Devos, Timothy
  • Sivgin, Serdar
  • Guglielmelli, Paola
  • Bensasson, Caroline
  • Khan, Mahmudul
  • Ronco, Julian Perez
  • Passamonti, Francesco
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Nothing Hurts Follow-Up like Follow-Up?

Nothing Hurts Follow-Up like Follow-Up?

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Physical activity initiated by employer and its health effects; an eight week follow-up study

Physical activity initiated by employer and its health effects; an eight week follow-up study

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

Hypersensitivity relief of MIH-affected molars using two sealing techniques: a 12-week follow-up

"Ardennes Follow-up Series"

Serie

"Ardennes Follow-up Series"

Verbundene Objekte